186 related articles for article (PubMed ID: 37447211)
61. Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening.
Konda VJ; Cherkezyan L; Subramanian H; Wroblewski K; Damania D; Becker V; Gonzalez MH; Koons A; Goldberg M; Ferguson MK; Waxman I; Roy HK; Backman V
Endoscopy; 2013 Dec; 45(12):983-8. PubMed ID: 24019132
[TBL] [Abstract][Full Text] [Related]
62. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
[TBL] [Abstract][Full Text] [Related]
63. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.
Lee RG
Am J Surg Pathol; 1985 Dec; 9(12):845-52. PubMed ID: 2416226
[TBL] [Abstract][Full Text] [Related]
64. Chronic Obstructive Pulmonary Disease and the Risk of Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma: A Primary Care Case-Control Study.
Menon S; Nightingale P; Trudgill N
J Clin Gastroenterol; 2019; 53(10):e451-e455. PubMed ID: 31008868
[TBL] [Abstract][Full Text] [Related]
65. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
[TBL] [Abstract][Full Text] [Related]
66. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
Mallick R; Patnaik SK; Wani S; Bansal A
Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
[TBL] [Abstract][Full Text] [Related]
67. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
68. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
[TBL] [Abstract][Full Text] [Related]
69. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
70. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
71. Clinical characteristics of young patients with early Barrett's neoplasia.
Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
[TBL] [Abstract][Full Text] [Related]
72. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
73. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
74. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
75. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
76. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
77. Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus.
Pinto R; Hauge T; Jeanmougin M; Pharo HD; Kresse SH; Honne H; Winge SB; Five MB; Kumar T; Mala T; Hauge T; Johnson E; Lind GE
Clin Epigenetics; 2022 Jun; 14(1):77. PubMed ID: 35701814
[TBL] [Abstract][Full Text] [Related]
78. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
Tokunaga M; Okimoto K; Akizue N; Ishikawa K; Hirotsu Y; Amemiya K; Ota M; Matsusaka K; Nishimura M; Matsushita K; Ishikawa T; Nagashima A; Shiratori W; Kaneko T; Oura H; Kanayama K; Ohta Y; Taida T; Saito K; Matsumura T; Chiba T; Mochizuki H; Arai M; Kato J; Ikeda JI; Omata M; Kato N
Sci Rep; 2021 Sep; 11(1):17671. PubMed ID: 34480065
[TBL] [Abstract][Full Text] [Related]
79. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
[TBL] [Abstract][Full Text] [Related]
80. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
